Very-Low-Level Viremia, Inflammatory Biomarkers, and Associated Baseline Variables: Three-Year Results of the Randomized TANGO Study.

"Potential conflicts of interest. R. W., M. U., J. O., R. Moodley, B. W., M. K., B. J., and M. A.-K. are employees of ViiV Healthcare or GSK and own stock in GSK. J. M. L. has received consulting fees and honoraria from Gilead, Janssen-Cilag, and ViiV Healthcare and travel support from Gilead. E. B. M. has received honoraria and travel support from Gilead, Janssen, MSD, and ViiV Healthcare. C. B. has received grants, paid to her institution, from Gilead; consulting fees and honoraria from Gilead and ViiV Healthcare; and travel support from Gilead, Merck, and ViiV Healthcare. J. S. M. has received honoraria from Gilead, Janssen, MSD, and ViiV Healthcare and travel support from Gilead and Janssen. S. S. has received grants from Gilead, GSK, Heidelberg ImmunoTherapeutics, INSTO, Kassenärztliche Vereinigung Nordrhein, RKI, and ViiV Healthcare; honoraria from Cepheid, Gilead, Janssen, and ViiV Healthcare; payment for expert testimony from Gilead; and travel support from Gilead, Janssen, and ViiV Healthcare. S. S. has also participated in advisory boards for Gilead and ViiV Healthcare and is a member or controller of Landeskommission AIDS North-Rhine Westphalia (NRW), AIDS Hilfe NRW, NÄAGNO, and Dagnä. P. S. is a complimentary worker on behalf of GSK. R. Moore certifies no potential conflicts of interest."

"Financial support. This work was supported by ViiV Healthcare. Financial support ."

"Trial registration: ClinicalTrials.gov , NCT03446573."